Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 172 participants.

Also called NCT02291237

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 172 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02291237
  • EudraCT 2013-004429-97
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, France, Germany, Israel, Italy, Netherlands, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT02291237. Randomized; quadruple masking; primary purpose treatment. Start 2015-02-05 (actual); primary completion 2017-01-20 (actual). Results posted on 2018-03-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy
Acronym
LIBERTY-HCM
Condition
Hypertrophic Cardiomyopathy
Intervention (Drug)
Eleclazine
Intervention (Drug)
Placebo
Lead sponsor
Gilead Sciences (class: industry)

Record details

Record id
cardio:ct-nct02291237
Content hash
d1fa4bf12e7569524f00ea9909bdb6805f6a3a1a03b2b3d59242c9f49f62d5b5